Oncotelic Therapeutics Q1 2026: Advances in AI, Oncology, and CNS Delivery

Oncotelic Therapeutics (OTCQB: OTLC) reported its first-quarter 2026 financial results and a corporate update, highlighting continued progress across its oncology, AI-enabled drug development, and advanced drug delivery initiatives. The company is advancing its Sapu Nano joint venture and nose-to-brain CNS delivery platform. Oncotelic maintained the previously established approximately $388 million fair value of its 45% ownership interest in GMP Biotechnology as of March 31, 2026, while pursuing capital-efficient growth across its diversified biotechnology platform. The company is a clinical-stage biopharmaceutical firm focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications. Its CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued patents. Oncotelic leverages its proprietary AI-enabled PDAOAI platform for research, biomarker discovery, and regulatory processes. Beyond internal programs, the company licenses and co-develops select drug candidates through strategic partnerships and joint ventures, including its 45% interest in GMP Bio. InvestorWire (IW), a specialized communications platform and part of the Dynamic Brand Portfolio @ IBN, distributed this news. IW provides advanced wire-grade press release syndication, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit InvestorWire.

To view the full press release, visit https://ibn.fm/DTVsF. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC. Oncotelic’s mission is to address high-unmet-need cancers with innovative, late-stage therapeutic candidates. Its PDAOAI platform supports research and regulatory processes through advanced data analysis. The company’s joint venture, GMP Bio, advances a complementary pipeline of therapeutic candidates, strengthening Oncotelic’s position in oncology and rare disease therapeutics. InvestorWire, one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivers access to a vast network of wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications solutions. IW brings its clients recognition and brand awareness by cutting through information overload.